Evaluation of the effect of double inhibition of angiotensin II AT1 receptor and neprilysin activity on sympatic nervous system activity in patient with heart failure (B2AN-SNS)

niversity Hospital Toulouse0 sites50 target enrollmentMarch 21, 2016

Overview

No summary available.

Registry

who.int

Start Date

March 21, 2016

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

niversity Hospital Toulouse

•Men or women of 18 years old or older with heart failure with symptomatic left ventricular systolic dysfunction (left ventricular ejection fraction \= 40 %) with :
•\-Functional class NYHA II and at least 2 hospitalizations for cardiac decompensation in the year with NT\-proBNP \=300 pg/ml (or BNP \=100 pg/ml) or usage of intravenous diuretics,
•\-Functional class NYHA III\-IV,
•\-Insufficiently controlled by alternative drug\-free therapies (surgery, cardiac resynchronization ...) or well managed drug therapies: angiotensin\-converting\-enzyme inhibitor, AT1 receptor of angiotensin II inhibitor diuretics or beta blockers.
•Patient member of his home social security scheme
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 25
•F.1\.3 Elderly (\>\=65 years) yes

•Patient who are receiving direct renin inhibitor like aliskiren
•Patient who are receiving a statin
•Patient who are receiving phosphodiestérase V inhibitors
•Patient who are receiving a potassium\-sparing drug
•Patient with medical history of angioedema with previous treatment by angiotensin\-converting\-enzyme inhibitor or AT1 receptor of angiotensin II inhibitor
•Hypersensitivity to any component of Entresto®
•Adult protected by the law
•Severe renal impairment (DFGe \<30 ml/min/1,73 m2\)
•Severe hepatic impairment, cirrhosis or cholestasis (Child\-Pugh C class)
•Patient with are receiving anticoagulant therapies or suffering from known hemostatic trouble